Patents by Inventor Kamil Önder
Kamil Önder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230349009Abstract: The present invention refers to a receptable for body fluids wherein inside the receptable an coronavirus deactivating composition is present in solid form, use of said receptable for the collection of saliva, a kit for collecting saliva samples comprising said receptable, the use of said kit for collecting saliva, especially saliva comprising viral RNA and a method for the detection of RNA or DNA.Type: ApplicationFiled: September 18, 2020Publication date: November 2, 2023Inventors: Daniel Wallerstorfer, Kamil Önder
-
Publication number: 20230236177Abstract: A Western Blot assay is performed by performing a probing process on a membrane containing target proteins, by contacting the membrane with a fluorescent resonant energy transfer (FRET) solution and allowing the probing process to proceed for a probing time period. The probing process results in a target protein becoming labeled with both a donor chromophore and an acceptor chromophore, which are effective as a donor-acceptor pair for FRET when so linked to the target protein. While performing the probing process, the labeled target proteins are measured by irradiating the membrane with an excitation light to excite the donor chromophores, wherein in each labeled target protein, the excited donor chromophore transfers energy to the acceptor chromophore by FRET and, in response, the labeled target protein emits an emission light. The intensity of the emission light is then measured. The light measured may be light emitted from the donor chromophore and/or light emitted from the acceptor chromophore.Type: ApplicationFiled: February 9, 2023Publication date: July 27, 2023Inventors: Michael Katzlinger, Kamil Önder
-
Patent number: 11604186Abstract: A Western Blot assay is performed by performing a probing process on a membrane containing target proteins, by contacting the membrane with a fluorescent resonant energy transfer (FRET) solution and allowing the probing process to proceed for a probing time period. The probing process results in a target protein becoming labeled with both a donor chromophore and an acceptor chromophore, which are effective as a donor-acceptor pair for FRET when so linked to the target protein. While performing the probing process, the labeled target proteins are measured by irradiating the membrane with an excitation light to excite the donor chromophores, wherein in each labeled target protein, the excited donor chromophore transfers energy to the acceptor chromophore by FRET and, in response, the labeled target protein emits an emission light. The intensity of the emission light is then measured. The light measured may be light emitted from the donor chromophore and/or light emitted from the acceptor chromophore.Type: GrantFiled: October 17, 2018Date of Patent: March 14, 2023Assignee: Molecular Devices (Austria) GmbHInventors: Michael Katzlinger, Kamil Önder
-
Publication number: 20220259679Abstract: An oligonucleotide, having a 5? terminus and a 3? terminus, wherein said oligonucleotide is detectably labeled and has a nucleotide sequence that consists essentially of one of the nucleotide sequences selected from SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:59 and SEQ ID NO:60.Type: ApplicationFiled: June 4, 2021Publication date: August 18, 2022Inventors: Kamil Önder, Sven Breunig
-
Publication number: 20200124591Abstract: A Western Blot assay is performed by performing a probing process on a membrane containing target proteins, by contacting the membrane with a fluorescent resonant energy transfer (FRET) solution and allowing the probing process to proceed for a probing time period. The probing process results in a target protein becoming labeled with both a donor chromophore and an acceptor chromophore, which are effective as a donor-acceptor pair for FRET when so linked to the target protein. While performing the probing process, the labeled target proteins are measured by irradiating the membrane with an excitation light to excite the donor chromophores, wherein in each labeled target protein, the excited donor chromophore transfers energy to the acceptor chromophore by FRET and, in response, the labeled target protein emits an emission light. The intensity of the emission light is then measured. The light measured may be light emitted from the donor chromophore and/or light emitted from the acceptor chromophore.Type: ApplicationFiled: October 17, 2018Publication date: April 23, 2020Inventors: Michael Katzlinger, Kamil Önder
-
Patent number: 10456379Abstract: The present invention relates to novel therapeutic agents suitable for use in the treatment of mammalian disease and in particular to novel therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes.Type: GrantFiled: December 3, 2015Date of Patent: October 29, 2019Assignee: Procomcure Biotech GmbHInventors: Kamil Önder, Roelf Datema
-
Patent number: 10322110Abstract: The present invention relates to therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes. In one particular embodiment, the pharmaceutical composition can have the structural moiety of formula (I) or a pharmaceutically-acceptable salt of said compound: wherein group A is selected from the formulae Group B is aryl, R1 is an optionally substituted aryl ring, an optionally substituted benzyl ring, CH3, or C2 to 6 alkyl, and R2 is hydrogen, an alkyl group, a halogen, or —(CH2)nN(CH3)2 where n is an integer from 1 to 3.Type: GrantFiled: December 3, 2015Date of Patent: June 18, 2019Assignee: Procomcure Biotech GmbHInventors: Kamil Önder, Roelf Datema, Dale Mitchell, Ivan Kondratov
-
Patent number: 10314820Abstract: The present invention relates to novel compounds of formula (I) suitable e.g. as therapeutic agents for use in the treatment of mammalian disease and in particular to novel therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes. The present invention also relates to processes for making said agents.Type: GrantFiled: December 3, 2015Date of Patent: June 11, 2019Assignee: Procomcure Biotech GmbHInventors: Kamil Önder, Roelf Datema, Dale Mitchell, Ivan Kondratov
-
Publication number: 20170368032Abstract: The present invention relates to novel therapeutic agents suitable for use in the treatment of mammalian disease and in particular to novel therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes.Type: ApplicationFiled: December 3, 2015Publication date: December 28, 2017Inventors: Kamil Önder, Roelf Datema, Dale Mitchell, Ivan Kondratov
-
Publication number: 20170340613Abstract: The present invention relates to novel compounds of formula (I) suitable e.g. as therapeutic agents for use in the treatment of mammalian disease and in particular to novel therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes. The present invention also relates to processes for making said agents.Type: ApplicationFiled: December 3, 2015Publication date: November 30, 2017Inventors: Kamil Önder, Roelf Datema, Dale Mitchell, Ivan Kondratov
-
Publication number: 20170334887Abstract: The present invention relates to novel therapeutic agents suitable for use in the treatment of mammalian disease and in particular to novel therapeutic agents suitable for use in the treatment of microbial infection in mammals. The present invention further relates to the use of pharmaceutical compositions comprising said agents in the treatment of medical conditions in mammals, in particular in the treatment of microbial infection. The agents and pharmaceutical compositions of the invention are of particular relevance in the treatment of diseases associated with antibiotic-resistant microbes.Type: ApplicationFiled: December 3, 2015Publication date: November 23, 2017Inventors: Kamil Önder, Roelf Datema